---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027044"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:17:38.070688+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Diffusion Pharma rejects 'woefully inadequate' unsolicited offer; LifeSci launches proxy contest for board control

## Summary
- Director Eric Francois resigns effective Dec 16, 2022; Board reduces from 7 to 6 members.
- Company reports active bidding stage in strategic review; encouraged by response from multiple parties.
- Board rejects unsolicited offer from LifeSci client as woefully inadequate; encourages LifeSci to join process.
- LifeSci commences proxy contest to replace board with its own nominees ahead of Dec 30, 2022 annual meeting.
- Annual meeting of stockholders set for December 30, 2022, two weeks later than previously announced.

## SEC filing metadata
- accession: 0001437749-22-027044
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027044/0001437749-22-027044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027044/dffn20221113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027044
- JSON: https://secwatch.observer/filing/0001437749-22-027044.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027044.txt

## Key facts
- Executive change
  Eric Francois resigned as director at CervoMed Inc..
  - Action: resigned
  - Role: director
  source text: On November 13, 2022, Eric Francois resigned from the board of directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) and all committees and subcommittees thereof, effective as of December 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774922027044/0001437749-22-027044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.